Search results
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 3 days agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 6 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 2 days agoThe American Society of Clinical Oncology held its annual conference in Chicago this past week,...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 6 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 3 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 4 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 6 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 7 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 6 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 24 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.